The rising prevalence in GLP-1 agonists for diabetes has generated a discussion about delivery routes : skin-applied devices versus tablets . Typically, GLP-1 drugs were exclusively available in pill form, but the emergence of transdermal delivery offers a new way. Skin applications might benefit individuals facing issues taking oral medications, t